Scinai Immunotherapeutics
Merav Kamensky, Senior Manager Quality Control, brings experience as a laboratory researcher at the University of Waterloo, Canada and in the biopharmaceutical industry including positions at Abic Biological Laboratories Teva Ltd and InSight Biopharmaceuticals Ltd. Prior to joining BiondVax in 2022, Merav led QC chemistry and biochemistry analytical operations at SciVac Therapeutics Inc. (VBI Vaccines Inc.) under cGMP conditions and supported FDA and Israel MoH audits.
Merav earned a BSc. and MSc. in Biotechnology and Agriculture from The Hebrew University of Jerusalem.
This person is not in any offices
Scinai Immunotherapeutics
1 followers
Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) is a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious diseases. With a state-of-the-art facility for biopharmaceutical product development and manufacturing and highly experienced pharmaceutical industry leadership, Scinai offers end-to-end boutique CDMO services in parallel to developing its own pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized VHH antibody (NanoAb) pipeline targeting diseases with large unmet medical needs. Company website: www.scinai.com